Research programme: T cell therapeutics - Adaptive Biotechnologies
Latest Information Update: 24 Nov 2015
At a glance
- Originator Adaptive Biotechnologies; Fred Hutchinson Cancer Research Center
- Class T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 19 Aug 2015 Early research in Cancer in USA (unspecified route)